Back

Patient views on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Lipoprotein(a) (1) Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Catriona Sian Jennings

University of Galway, Galway (Ireland)

5 More presentations in this session

Presentation thumbnail
Combined effects of lipoprotein(a) and HDL cholesterol on cardiovascular mortality: a longitudinal study
Professor B. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
High lipoprotein(a) and high BMI jointly confer the highest risk of ASCVD in both primary and secondary prevention
Mr P. Thomas (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Extra-virgin olive oil intake and lipoprotein A levels in the PREDIMED-Plus study
Doctor J. Diaz-Gutierrez (Huelva, ES)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a), high-sensitive c reactive protein, and long-term survival after coronary artery bypass grafting
Doctor S. Yuan (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Impact of lipoprotein(a) concentrations on atherosclerotic cardiovascular disease onset: a survival analysis
Doctor V. Zorzanelli Rocha (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Lipoprotein(a) (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Congress Presentation
Should we intervene early in patients with asymptomatic aortic stenosis?
thumbnail
Congress Presentation
Cardiovascular prevention in older adults

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources